Non-Small Cell Lung Cancer | Oncology Today with Dr Neil Love: Management of RET Fusion-Positive Non-Small Cell Lung Cancer

Featuring an interview with Dr Justin Gainor, including the following topics:

• Ongoing Phase III trials of selective RET inhibitors for non-small cell lung cancer (NSCLC): Potential effects on survival (0:00)
• Significance of non-fusion RET abnormalities in NSCLC (3:33)
• Clinical impact of tumor-agnostic targeted therapy (5:11)
• Incidence and management of chylothorax in patients undergoing treatment with RET inhibitors (8:46)
• Therapeutic approach for patients with RET-rearranged NSCLC and brain metastases (15:24)
• Appropriate use of checkpoint inhibitors for patients with RET-rearranged NSCLC and disease progression on a RET inhibitor (16:45)
• Adjuvant therapy for RET-rearranged NSCLC (26:23)
• Case: A woman in her mid 60s with no smoking history with NSCLC with a RET fusion and disease progression after a response to carboplatin and pemetrexed (31:07)
• Case: A woman in her early 50s with no smoking history with NSCLC with a RET fusion and liver lesions who previously received cisplatin/pemetrexed and pembrolizumab (36:40)
• Case: A woman in her late 60s with NSCLC with a RET fusion and liver and brain metastases (43:28)

CME information and select publications